Exogen (US) files premarket approval (PMA) supplement for SAFHS 2000:
This article was originally published in Clinica
Exogen (US) has filed a PMA supplement with the US FDA for the SAFHS 2000, a second-generation model of its Sonic Accelerated Fracture Healing System. The original device, which is being introduced into Europe, will be marketed in Japan by Teijin which will also develop Exogen's mechanical stress technology. The latter device is in a pilot US clinical trial in post-menopausal women to reduce related bone density decline.
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.